

H1N1-infected Patients in ICU and Their Clinical Outcome

Talkad Chandrashekar Nagesh Kumar, Nanjangudu Subramanya Shivakumar, Telugu Sitaram Deepak¹, Krishnappa Rashmi², Melur Shivakumar Goutam³, Ganigar Vivek

Departments of Internal Medicine, ¹Anesthesia and Critical Care, ²Pathology, ³Community Medicine, MS Ramaiah Medical College and Memorial Hospital, Bangalore, Karnataka, India

Abstract

Background: The swine flu (H1N1) with rapid spread and panic in population is truly global pandemic, affected mainly younger population. There is need to accumulate evidence regarding patient's intensive care parameters for effective management of newer strains of influenza viral infections. Hence an observed retrospective record analysis of confirmed H1N1 patients admitted to intensive care unit (ICU) of a tertiary care centre is done. **Aims:** The study was designed to study the profile and pattern of H1N1 patients admitted to ICU and to study the distribution and associated factors with treatment outcomes. **Materials and Methods:** The demographic, clinical, and laboratory data of 32 (RT-PCR confirmed) H1N1 cases were collected and analyzed using Fischer's exact test/paired *t* test between survivors and nonsurvivors to know their significance. This data included criteria for admission to ICU, type of lung injury, mode of oxygenation, antiviral, and other drugs used. **Results:** There were 11 males and 21 female. Age ranged from 19 to 72 years. Age group of 15–45 years had most cases (78%) and mortality (60%). Most common symptoms were fever and breathlessness (100%). The mean duration of breathlessness was statistically significant ($P = 0.037$) between two groups. Most common signs were tachycardia and tachypnea. The 75% cases developed acute respiratory distress syndrome (ARDS), of this 16% survived. Among these fatal cases nine were positive for procalcitonin (PCT) ($P = 0.006$). The rest of 25% developed acute lung injury (ALI) and recovered completely ($P = 0.0001$). **Conclusion:** Fever and breathlessness were the main presenting complaints. Tachypnea and tachycardia as clinical signs predict development of respiratory complications. Arterial blood gas analysis (ABG) and $\text{PaO}_2/\text{FiO}_2$ were important in deciding severity of lung injury and mode of ventilation. ARDS was observed to be the main cause of mortality in this study. Serum PCT level estimation is useful in determining outcome.

Keywords: Acute lung injury, Acute respiratory distress syndrome, Arterial blood gas analysis, H1N1, Intensive care unit

Address for correspondence: Dr. Talkad Chandrashekar Nagesh Kumar, House #- 861, 1st floor, 1st Main Road, Kengeri Satellite Town, Bangalore, Karnataka, India. E-mail: tcnk_861@yahoo.com

Introduction

The first case of novel strain of influenza A virus of swine origin (H1N1) was reported in Mexico during March 2009.^[1] World health organization (WHO) declared a pandemic, with alert level of phase 6 within 3 months due to its global spread.^[2] Most cases of H1N1 influenza infection present as mild or subclinical pneumonia, but some present as severe community acquired pneumonia

(CAP) and require admission to intensive care unit (ICU) usually. The main reason for admission to ICU is due to acute lung injury/acute respiratory distress syndrome (ALI/ARDS). It causes primary viral pneumonia with secondary bacterial infections (20–30%) and it is notoriously known to affect younger population.^[3–6] In India, this pandemic started from August 2009, with index case reported from Pune, and this epidemic spread to other parts of the country quickly.^[7] There was reemergence of H1N1 during early 2012.

Pneumonia is one of the common and serious complications of H1N1.^[8] The increased incidence of critical illness along with high transmissibility rate and rapid rise in the cases over a short period of time exerted significant stress on hospital resources, especially on intensive care.^[9] There is need to accumulate evidence regarding patient's intensive care parameters for

Access this article online

Quick Response Code:



Website:
www.najms.org

DOI:
10.4103/1947-2714.100984

effective management of newer strains of influenza viral infections. Hence an observed retrospective record analysis of confirmed H1N1 patients admitted to ICU of a tertiary care centre, from August 2009 to April 2011, was undertaken with the following aims. The study was designed: to study the profile and pattern of H1N1 patients admitted to ICU and to study the distribution and associated factors (patient care factors and laboratory parameters) with treatment outcomes (survivors vs. nonsurvivors).

Materials and Methods

The present study had ethical clearance from institutional (MS Ramaiah) ethical committee. The present study is a retrospective study of successive, confirmed H1N1 patients with respiratory complication admitted to ICU of a tertiary care centre from August 2009 to April 2011. All 32 cases were RT-PCR confirmed at NIMHANS, Bangalore. Arterial blood gas analysis (ABG) was done at regular intervals to classify respiratory failure as either ARDS/ALI in accordance to American-European consensus conference.^[10] The ratio of PaO₂/FiO₂ at the time of initiation of ventilatory support was noted. Of the 32 cases, 24 (75%) cases met ARDS criteria and 8 (25%) cases met ALI criteria. The demographic, clinical, laboratory and radiological data were collected from medical records and analyzed. The statistical analysis was done for all parameters for outcome among survivors versus nonsurvivors. All cases were treated with oral oseltamivir 75 mg bid, from the day of admission, in accordance with the WHO criteria.^[11] All the patients were treated with broad spectrum antibiotics to cover coinfection/secondary bacterial infections and inotropic support for shock and ventilatory support given according to patient requirement. Serum procalcitonin (PCT), sputum, and blood culture were done to rule out bacterial sepsis at admission and at regular intervals. All other ICU patients, nurses, doctors, and other supporting staff were vaccinated and close contacts were treated prophylactically with oral oseltamivir according to WHO recommendations.

Statistical analysis

Descriptive statistics

Qualitative data like gender, morbidities, normal and abnormal laboratory values, and outcome were analyzed and presented as frequency and percentages. Quantitative data like age, laboratory values, and duration of hospital stay are presented as mean and standard deviation with 95% confidence intervals.

Analytical Statistics

To test association between clinical outcomes, laboratory values, hospital care management parameters the

Independent 't' test was applied. Fischer's exact test was applied to test association between clinical outcomes and qualitative variables. The test was considered significant at $P < 0.05$.

Results

It was observed that among the 1171 medical cases admitted to ICU during the study period, 17.9% (210/1171) were suspected to be suffering from flu, among them 2.7% (32/1171) cases were positive for H1N1. Proportion of positive cases among the suspected cases was 15.2% (32/210). Table 1 shows demography, comorbidities/risk factors and serum PCT value among the 32 H1N1 positive patients requiring intensive care. APACHE II score was calculated for all; it ranged from 9–18, and was not statistically significant between two groups. The male:female ratio was 1:1.9. The case fatality rate in males was 73.7% (8/11), in comparison to females with 57.2% (12/21) but is not statistically significant. The patient's age ranged from 19 to 72 years. Distribution of cases among age groups is shown in Figure 1, maximum number of cases and fatality were in the age group of 15–45 years, that is, 78.1% (25/32) and 60% (15/32), respectively. Most patients had fever (100%), breathlessness (100%), and cough (75%) as presenting complaints. The mean duration of breathlessness is statistically significant ($P = 0.037$) between two groups. The first case was reported in August 2009 and maximum number of cases and fatalities were reported during April to September 2010, that is, 65.6% (21/32) and 71.4% (15/21), respectively [Figure 2]. When cases with and without comorbidities were compared, outcome was not statistically significant ($P = 0.431$) [Table 1].

All the patients had tachycardia and tachypnea. Respiratory system examination showed bilateral/unilateral, diffuse/focal rhonchi and/ or crepitations. The mean of laboratory parameters such as hemoglobin (12 g/dl), total leukocyte count (7311 cells/mm³), and differential count (neutrophils - 72.7%, lymphocyte - 32%) was within the normal range. Serum creatinine was raised in eight cases; none progressed to acute kidney injury. Mild elevation of AST (Aspartate aminotransferase) and ALT ((Alanine aminotransferase) was seen in seven cases. The PCT was positive in 28.1% (9/32) and none of them were culture positive. Incidentally all PCT positive cases succumb to illness, with significant P value ($P = 0.006$). All the 32 cases showed varying degree lung infiltrations suggestive bronchopneumonia or ALI or ARDS on chest X-ray. The mean number of days in ICU was 5.5 and 7.6 days in survivors versus nonsurvivors, respectively. The mean number of days on ventilator support was 4.3 and 7.1 days in survivors versus nonsurvivors, respectively [Table 2]. The mean number of days in hospital was




Figure 1: Bar diagram showing distribution of cases among different age groups




Figure 2: Bar diagram showing distribution of cases during months of epidemic

Table 1: Demography, comorbidities/risk factors and serum procalcitonin value among the cases

Characteristics	Survivors (n = 12)	Nonsurvivors (n = 20)	Total	P value
Gender				
Male	3 (27.3)	8 (73.7)	11 (34.4)	0.387
Female	9 (42.8)	12 (57.2)	21 (65.6)	
Total	12 (37.5)	20 (62.5)	32 (100)	
Comorbidities/risk factors				
Diabetes mellitus	1	4	5	0.431
Hypertension	2	5	7	
Ischemic heart disease	None	1	2	
Hypothyroidism	1	None	1	
Pregnancy	1	2	3	
Serum procalcitonin levels				
Positive	0	09 (100)	09 (100)	0.006
Negative	12 (52.2)	11 (47.8)	23 (100)	

*Fischer's exact test Among the 32 H1N1 positive patients admitted in ICU it was observed that 12 (37.5%) survived and 20 (62.5%) succumbed to the disease. There was no statistically significant association between treatment outcomes and gender among the study subjects. Serum procalcitonin alone being significant ($P < 0.05$)

8.5 and 7.7 days in survivors versus nonsurvivors, respectively. ARDS was seen in 75% (24/32) of study group, all were managed by invasive ventilation (IPPV/CMV) in ARDS mode (low tidal volume and high peep). Among ARDS cases four cases recovered. ALI was seen in eight cases, all are managed by noninvasive ventilatory support (CPAP/ BiPAP) and all cases recovered ($P = 0.0001$). To summarize, out of 32 patients with respiratory failure, 12 recovered and 20 succumbed to H1N1, all nonsurvivors had extensive lung damage in the form of ARDS ($P = 0.0001$).

Discussion

The emergent pandemic H1N1-2009 virus is challenging to the medical community around the world. Because of its unusual rapidity of spread specially among young and previously healthy patients, who were considered as low risk group for influenza-induced complications.^[12-14] In the present study, majority (78.1%) of the cases were seen in age group of 15-45 years, was fatal in 60% (15/25). This is similar to

study by Choudasama *et al.*, in which mean age was 29.4 years^[15] and by Chako *et al.* with cases in the age group of 19-55 years.^[16] This may be due to immunity in older persons due to pre-2009 H1N1 influenza virus exposure. In future years, as the virus evolves, the epidemiology of H1N1-infection may affect older persons to a greater extent.^[17-20]

In the present study, fatality was more in male (73.7%). This is in contrast to a recent Indian study where fatality was more in female, that is, 75%.^[21] The chief presenting complaints were fever, breathless (100% each), and cough (75%); as comparable to studies by Rao *et al.* and Puvanalingam *et al.*^[7,21] Underlying diseases/risk factor like diabetes mellitus, hypertension, ischemic heart disease, bronchial asthma, and pregnancy were seen in 46.8%, as comparable to 52.6% in Kerkhove *et al.* global pooled analysis of H1N1.^[22] Among vital parameters all our patients had tachypnea and tachycardia similar to observation by Bewick *et al.* study.^[23] The laboratory data such as complete blood count were within normal range, as comparable to other studies.^[23] So

Table 2: Age, symptoms, signs, PaO₂/FiO₂ ratio, and patient care parameters among two groups of patients

Characteristics	Survivors (n = 12) mean (SD)	Nonsurvivors (n = 20) mean (SD)	Total mean (SD)	P value	95% CI	
Age (n = 32)	36.0 (10.4)	37.1 (15.7)	36.55	0.82*	8.9	11.1
Duration of symptoms in days						
Fever	4.82 (1.82)	5.5 (1.95)	5.15 (100)	0.337*	-2.19	0.77
Cough	3.7 (1.48)	4.2 (1.60)	3.95 (75)	0.509*	-1.71	0.87
Expectoration	3 (0.81)	3.6 (1.75)	3.2 (40.6)	0.515*	-2.58	1.35
Breathlessness	1.3 (0.50)	2 (0.86)	1.65 (100)	0.037*	-1.23	-0.41
Signs						
Pulse rate (bt/min)	102 (11.9)	104 (17.7)	103 (100)	0.754	-13.67	10.0
Respiratory rate (cyc/min)	30.7 (4.07)	33.8 (7.07)	32.2 (100)	0.184	-7.63	1.53
PaO ₂ /FiO ₂ values and Severity of lung damage						
ARDS † (75%) mean = 136.1	4 (16.7%)	20 (83.3%)	24 (100%)	0.000	42.75	111.8
ALI ‡ (25%) mean = 255.5	8 (100%)	Nil	8 (100%)			
No. of days in ICU	5.5 (3.96)	7.65 (5.59)	6.5	0.254	-5.922	1.622
No. of days on ventilator	4.33 (3.57)	7.10 (5.63)	5.71	0.139	-6.482	0.948
Ventilator mode						
ARDS † MODE	4 (16.6)	20 (83.3)	24	0.000		
NIV§	8 (100)	None	08			

*Independent 't' Test †Acute respiratory distress syndrome, ‡Acute lung injury, §Noninvasive ventilation

this suggests that routine laboratory parameters did neither contribute to diagnosis nor management of H1N1 influenza.

In this study, PCT was positive in nine fatal cases, other studies also highlights importance of secondary bacterial pneumonias, such as staphylococcus aureus and streptococcus pneumonia. [5,24] But evidence of bacterial coinfection was seen in fewer than 30%, suggesting that primary viral pneumonia is often important. [25] All our cases were culture negative, this could be due to use of broad spectrum antibiotics. The chest X-ray of all (100%) the patients showed varying degree of lung infiltrations as comparable to study by Choudasama *et al.* with 93% showed lung infiltrations. [15] The mean of PaO₂/FiO₂ was 136 in ARDS group, is comparable to previous study, that is, 147. [5] ARDS secondary to H1N1-related viral pneumonia is the leading cause of mortality in the present study and which is similar to previous studies. [5,24] ALI is a significant cause of morbidity and it can progress to ARDS. [5] Tablet oseltamivir was started immediately on an average 5 days postsymptomatic; this delay of 5 days is due to recognition of H1N1-infection by general practitioners. This could have contributed to rapid progression and development of complications in our cases. Previous studies have concluded early initiation of oral oseltamivir reduced morbidity and mortality. [11,26]

Limitations

This study is a retrospective observational study of patients treated in our ICU and findings have limited external validity in terms of generalizations, as it is a single centre study.

Conclusion

Fever and breathlessness were the main presenting complaints tachypnea and tachycardia, as clinical signs predict development of respiratory complications in H1N1 swine flu. ABG and PaO₂/FiO₂ are important in deciding severity of lung injury and mode of ventilation. ARDS was observed to be the main cause of mortality in the present study. Serum PCT level estimation is also useful in determining outcome.

References

- Centers for Disease Control and Prevention (CDC). Outbreak of swine-origin influenza A (H1N1) virus infection- Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep 2009;58:467-70.
- World Health Organization. World now at the start of 2009 influenza pandemic. In statement to the press by WHO director, 2009. (Accessed December 12, 2011, at http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_2009061/en/index.html)
- Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, *et al.* Emergence of novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-15.
- Miller E, Hoschler K, Hardelid P, Stanford E, Andrew A, Zambon M. Incidence of 2009 pandemic influenza A (H1N1) in England: A cross sectional serological study. Lancet 2010;375:1100-8.
- Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, *et al.* Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009;302:1872-9.
- Kotsimpos T, Waterer G, Jenkins C, Kelly PM, Cheng A, Hancox RJ. Influenza A /H1N1_09: Australia and New Zealand's winter of discontent. Am J Respir Crit Care Med 2010;181:300-6.

7. Puvanalingam A, Rajendiran C, Sivasubramanian K, Ragunathanan S, Suresh S, Gopalakrishnan S. Case Series Study of the Clinical Profile of H1N1 Swine Flu Influenza. *J Assoc Physicians India* 2011;59:14-8.
8. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. *Am J Med* 2008;121:258-64.
9. Dominguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espisa-Perez L, de la Torre A, *et al.* Critically ill patients with 2009 Influenza A (H1N1) in Mexico. *JAMA* 2009;302:1880-7.
10. Bernard GR, Artigas A, Bregham KL, Carlet J, Falke K, Hudson L, *et al.* The American-European consensus conference on ARDS. Definitions, Mechanisms, relevant outcomes and clinical trial coordination. *Am J Respir Crit Care Med* 1994;149:818-24.
11. WHO recommendations for Pharmacological management of Pandemic (H1N1) 2009 influenza and other influenza viruses; 20 August 2009. (Accessed December 25, 2011 at http://www.leb.euro.who.int/h1n1_guidelines_pharmacological_mng.pdf)
12. Chowell G, Bertozzi SM, Colchero MA, Lopez GH, Alpuche AC, Hernandez M, *et al.* Severe respiratory disease concurrent with the circulation of H1N1 influenza. *N Engl J Med* 2009;361:674-9.
13. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quiñones-Falconi F, Bautista E, *et al.* Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. *N Engl J Med* 2009;361:680-9.
14. Michaelis M, Doerr H, Cinatl JJ. Novel swine - origin influenza a virus in humans: Another pandemic knocking at door. *Med Microbiol Immunol* 2009;198:175-83.
15. Choudasama RK, Patel UV, Verma PB. Hospitalizations associated with 2009 influenza A (H1N1) and seasonal influenza in Saurashtra region, India. *J Infect Dev Ctries* 2010;23:834-41.
16. Chacko J, Gagan B, Ashok E, Radha M, Hemanth HV. Critically ill patients with 2009 H1N1 infection in an Indian ICU. *Indian J Crit Care Med* 2010;14:77-82.
17. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, *et al.* Cross-reactive antibody responses to 2009 pandemic H1N1 influenza virus. *N Engl J Med* 2009;361:1945-52.
18. Ross TM, Mohmood K, Crevar CJ, Schneider OK, Heaton PM, Bright RA. A trivalent virus like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. *PLoS One* 2009;4:e6032.
19. Skountzou I, Koutsonanos DG, Kim JH, Powers R, Satyabhama L, Maseoud F, *et al.* Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A(H1N1) influenza virus. *J Immunol* 2010;185:1642-9.
20. Jennings LC, Anderson TP, Beynon KA, Chua A, Laing RT, Werno AM, *et al.* Incidence and characteristics of viral community acquired pneumonia in adults. *Thorax* 2008;63:42-8.
21. Jagannatha Rao SR, Rao MJ, Swamy N, Umopathy BL. Profile of H1N1 infection in tertiary care center. *Indian J Pathol Microbiol* 2011;54:323-5.
22. Van Kerkhove MD, Vandemaële KA, Shinde V, Jaramillo GG, Koukounari A, Donnelly CA, *et al.* Risk Factors for Severe Outcomes following 2009 Influenza A (H1N1) Infection: A Global Pooled Analysis. *PLoS Med* 2011;8:e1001053.
23. Bewick T, Myles P, Greenwood S, Nguyen-Van-Tam JS, Brett SJ, Semple MJ, *et al.* Clinical and laboratory features distinguishing pandemic H1N1 influenza - related pneumonia from inter-pandemic community acquired pneumonia in adults. *Thorax* 2011;66:247-52.
24. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, *et al.* Factors associated with death or hospitalisation due to pandemic 2009 influenza. *JAMA* 2009;302:1896-902.
25. Centers for Disease Control and Prevention (CDC). Bacterial coinfections in lung tissue specimens from fatal cases of swine-origin pandemic influenza A (H1N1) May-August 2009. *MMWR Morb Mortal Wkly Rep* 2009;58:1071-4.
26. Sertogullarindan B, Ozbay B, Gunini H, Sunnetcioglu A, Arisoy A, Bilgin HM, *et al.* Clinical and prognostic features of patients with pandemic 2009 influenza A (H1N1) virus in intensive care unit. *Afr Health Sci* 2011;11:163-70.

How to cite this article: Talkad NC, Nanjangudu SS, Telugu DS, Krishnappa R, Melur GS, Ganigar V. H1N1-infected patients in ICU and their clinical outcome. *North Am J Med Sci* 2012;4:394-8.

Source of Support: Nil. **Conflict of Interest:** None declared.